The purpose of the present study is to assess the roles of protein kinase C (PKC) isoforms, especially PKCδ and α, and 20-kD myosin light chain (MLC20) phosphorylation in the mechanism of cerebral vasospasm following subarachnoid hemorrhage (SAH). We had shown that those PKC isoforms are involved in the development of cerebral vasospasm. Using PKC isoform-specific inhibitors in a ‘two- hemorrhage’ canine model, we examined changes in the development of cerebral vasospasm, translocation of PKC isoforms and MLC20 phosphorylation level in canine basilar arteries. A PKC inhibitor (5 µM rottlerin for PKCδ or chelerythrine for PKCα) was injected into the cisterna magna on day 4 before the second hemorrhage. The treatment was continued daily until day 7. Rottlerin inhibited the initial phase of vasospasm and PKCδ translocation, but did not significantly inhibit PKCα translocation. Chelerythrine inhibited cerebral vasospasm, and the translocation of both PKCδ and α throughout the entire course of the study. Although cerebral vasospasm after SAH was inhibited by each PKC inhibitor, the MLC20 phosphorylation level remained elevated as in the untreated hemorrhage-control study. We conclude that cerebral vasospasm following SAH depends on PKCδ and α, while the enhancement of MLC20 phosphorylation contributes little to this form of vasospasm.

Keywords:
Angiography, Chelerythrine, Myosin light chain, Phosphorylation, Protein kinase C inhibitor, Protein kinase C isoform, Rottlerin, Subarachnoid hemorrhage, Vasospasm, Western blotting
1.
Nishizawa S, Peterson JW, Shimoyama I, Uemura K: Relation between protein kinase C and calmodulin systems in cerebrovascular contraction: Investigation of the pathogenesis of vasospasm after subarachnoid hemorrhage. Neurosurgery 1992;31:711–716.
2.
Nishizawa S, Nezu N, Uemura K: Direct evidence for a key role of protein kinase C in the development of vasospasm after subarachnoid hemorrhage. J Neurosurg 1992;76:635–639.
3.
Nishizawa S, Yamamoto S, Yokoyama T, Ryu H, Uemura K: Chronological changes of arterial diameter, cGMP, and protein kinase C in the development of vasospasm. Stroke 1995;26:1916–1921.
4.
Nishizawa S, Obara K, Nakayama K, Koide M, Yokoyama T, Yokota N, Ohta S: Protein kinase Cδ and α are involved in the development of vasospasm after subarachnoid hemorrhage. Eur J Pharmacol 2000;398:113–119.
5.
Nishizawa S, Obara K, Nakayama K, Koide M, Ohta S, Yokoyama T: Which protein kinase C isoforms are involved in the development of vasospasm after subarachnoid hemorrhage? Acta Neurochirur 2001;77(suppl):21–24.
6.
Nishizuka Y: The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature 1984;308:693–698.
7.
Nishizuka Y: The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988;334:661–665.
8.
Katsuyama H, Morgan KG: Mechanism of Ca2+-independent contraction in single permeabilized ferret aorta cells. Circ Res 1991;72:651–657.
9.
Andrea JE, Walsh MP: Protein kinase C of smooth muscle. Hypertension 1992;20:585–595.
10.
Khalil RA, Lajoie C, Resnick MS, Morgan KG: Ca2+-independent isoforms of protein kinase C differentially translocate in smooth muscle. Am J Physiol 1992;263:C714–C719.
11.
Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992;258:607–614.
12.
Driska SP, Aksoy MO, Murphy RA: Myosin light chain phosphorylation associated with contraction in arterial smooth muscle. Am J Physiol 1981;240:C222–C233.
13.
Horowitz A, Menice CB, Laporte. R, Morgan KG: Mechanisms of smooth muscle contraction. Physiol Rev 1996;76:967–1003.
14.
Butler WE, Peterson JW, Zervas NT, Morgan KG: Intracellular calcium, myosin light chain phosphorylation, and contractile force in experimental cerebral vasospasm. Neurosurgery 1996;38:781–787.
15.
Sato M, Tani E, Fujikawa H, Kaibuchi K: Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res 2000;87:195–200.
16.
Varsos VG, Liszczak TM, Han DH, Kistler JP, Vielma J, Black PM, Heros RC, Zervas NT: Delayed cerebral vasospasm is not reversible by aminophylline, nifedipine, or papaverine in a ‘two-hemorrhage’ canine model. J Neurosurg 1983;58:11–17.
17.
Nakayama K: Active and passive mechanical properties of ring and spiral segments of isolated dog basilar artery assessed by electrical and pharmacological stimulations. Blood Vessels 1988;25:285–298.
18.
Frasch SC, Henson PM, Kailey JM, Richter DA, Janes MS, Fadok VA, Bratton DL: Regulation of phospholipid scramblase activity during apoptosis and cell activation by protein kinase Cdelta. J Biol Chem 2000;275:23065–23073.
19.
Gschwendt M, Muller HJ, Kielbassa K, Zang R, Kittstein W, Ricke G, Marks F: Rottlerin, a novel protein kinase inhibitor. Biochem Biophys Res Commun 1994;199:93–98.
20.
Gschwendt M, Kittstein W, Marks F: Elongation factor-2 kinase: Effective inhibition by the novel protein kinase inhibitor rottlerin and relative insensitivity towards staurosporine. FEBS Lett 1994;338:85–88.
21.
Keenan C Goode N, Pears C: Isoform specificity of activators and inhibitors of protein kinase Cγ and δ. FEBS Lett 1997;415:101–108.
22.
Herbert JM, Augereau JM, Gleye J, Maffrand JP: Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 1990;172:993–999.
23.
Eckly-Michel AE, Bec AL, Luginer C: Chelerythrine, a protein kinase C inhibitor, interacts with cyclic nucleotide phosphodiesterases. Eur J Parmacol 1997;324:85–88.
24.
Fryer RM, Schultz JEJ, Hsu AK, Gross GJ: Importance of PKC and tyrosine kinase in single or multiple cycles of preconditioning in rat hearts. Am J Physiol 1999;276:H1229–H1235.
25.
Obara K, Hata S, Sato K, Koide M, Ishii K, Nakayama K: Contractile potentiation by endothelin-1 involves protein kinase C-δ activity in the porcine coronary artery. Jpn J Physiol 1999;49:175–183.
26.
Obara K, de Lanerolle P: Isoproterenol attenuates myosin phosphorylation and contraction of tracheal muscle. J Appl Physiol 1989;66:2017–2022.
27.
Hime JM: The dog; in UFAW (ed): The UFAW Handbook on the Care and Management of Laboratory Animals. Edinburgh, Churchill Livingstone, 1972, pp 309–327.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.